Siramesine H Lundbeck.
Siramesine is a sigma2 opioid agonist under development by H Lundbeck as a potential treatment for anxiety 11678721. In March 1998, the compound was licensed to Forest Laboratories under a strategic alliance [282593]. In August 2000, siramesine entered phase II trials [378814]. Phase III trials are expected to take place in 2002 [387270]. A series of compounds have been synthesized by Lundbeck, the most potent of which may serve as a backup compound [179036].
Heading
C
C
moore11@globalnet.co.uk
D000818:Animals; D014151:Anti-Anxiety Agents / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D017480:Receptors, sigma / Q000819:agonists*; D013141:Spiro Compounds / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship
D014151:Anti-Anxiety Agents; D007211:Indoles; C109644:Lu 28-179; D017480:Receptors, sigma; D013141:Spiro Compounds